Rapid Uptake Products (RUPs)

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date. Click here to read the technical notes.

The HIN is supporting the adoption of the following innovations on the RUP Programme from April 2021 to March 2023:

1. Lipid Management : High Intensity Statins, Ezetimibe and PCSK9 inhibitors
2. Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
3. Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab